"When diagnoses rise shortly after starting a medication, that pattern often reflects finding something that was already there," said Rashmi Roy, MD, FACS, co-author of the white paper
10.14309/00000434-201810001-01342 38 GirmanC
Glucagon-like peptide-1 (GLP-1) receptor agonistsincluding semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda)along with tirzepatide (Mounjaro, Zepbound), a dual GIP/GLP-1 receptor agonist, have transformed the management of type 2 diabetes and obesity
Working with George Karavetsos, former director of FDAs Office of Criminal Investigations and a federal prosecutor, PSM analyzed the FDAs import records and related databases to investigate the origin, legality, and intended use behind the weight loss drug ingredients entering the U.S